Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Trial Profile

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Diabetic nephropathies; Hypertension
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms ASPIRE-HIGHER; AVOID
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Sep 2010 Results from the sub-study that investigated the effect of treatment on renal function presented at the 46th Annual Meeting of the European Association for the Study of Diabetes
    • 24 Oct 2009 Results of an economic analysis were presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 07 Sep 2008 Results have been presented at EASD 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top